Estrella Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023
Selling, General & Admin	3.01	2.81	3.2	0.66
Research & Development	10.24	10.25	4.11	10.45
Total Operating Expenses	13.25	13.06	7.31	11.11
Operating Income	-13.25	-13.06	-7.31	-11.11
Pretax Income	-13.25	-13.06	-7.31	-11.11
Provision for Income Taxes	0	0	0	-
Net Income	-13.25	-13.06	-7.31	-11.11
Net Income to Common	-13.25	-13.06	-7.31	-11.11
Shares Outstanding (Basic)	38	37	27	1
Shares Outstanding (Diluted)	38	37	27	1
Shares Change (YoY)	5.69%	35.85%	1809.14%	-
EPS (Basic)	-0.34	-0.35	-0.27	-36.35
EPS (Diluted)	-0.34	-0.35	-0.27	-36.35
Free Cash Flow	-	-1.79	-16.07	-1.34
Free Cash Flow Per Share	-	-0.05	-0.59	-0.94
EBITDA	-13.25	-13.06	-7.31	-11.11
EBIT	-13.25	-13.06	-7.31	-11.11
Effective Tax Rate	-0.01%	-0.01%	-0.02%	0.00%

SEC Filings: 10-K · 10-Q